Navigation Links
Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
Date:2/6/2012

AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focusing on oncology and cardiology, plans to report preliminary results for its fourth quarter and fiscal year 2011 on Thursday, February 23, 2012.

Company management will host a conference call at 4:30 p.m. Eastern time on the same day to discuss results for the periods, which ended December 31, 2011. Select preliminary unaudited results will be issued in a press release prior to the call.

Vermillion's president and chief executive officer, Gail Page, will host the call, followed by a question and answer period.

Date: Thursday, February 23, 2012
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-677-8143
International: 1-303-223-2680
Conference ID#: 21576618

The conference call will be broadcast simultaneously here and available for replay via the investor section of the company's Web site at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call and until March 8, 2012.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21576618 

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its well-known scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Investor Relations:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860
Email Contact


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Completes the Acquisition of Correlogic Systems Ovarian Cancer Diagnostics Business
2. Vermillion Reports Results for Third Quarter 2011
3. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
4. Vermillion Engages Liolios Group to Lead Investor Relations Program
5. Vermillion Enhances Management Team With A Key Addition
6. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
7. Vermillion Reports Financial Results for the First Quarter 2011
8. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
9. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
10. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
11. Vermillion Announces $21.8 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 via Discovery ... churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County ... Dr. Daniel A. Potter -- are proud of the recent release of their 2014 ... April, SART published the latest verified data for 375 U.S. member clinics. ...
(Date:4/29/2016)... ... 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and sponsor ... the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is the ... protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
Breaking Medicine News(10 mins):